|Slideshows|November 19, 2020

6 Predictions for Digital Psychiatry in 2021

Against a sea change in real-world practice of technology in psychiatry, John Torous, MD, MBI, shares what clinicians can expect next.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

No Screens Before Bed: Teen Smartphone Use at Bedtime Predicts Overnight Phone Activity

ByLeah Kuntz,Gina M. Mathew, PhD

June 15th 2026

Artificial Intelligence in Psychopharmacology: Promise and Pitfalls, With Roy Perlis, MD

ByJoseph F. Goldberg, MD,Roy Perlis, MD

June 10th 2026

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

ByLeah Kuntz

June 8th 2026

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

ByMark Gerstein, PhD

June 5th 2026

Harm Reduction for Behavioral Addiction in the Digital Age

ByHector A. Colon-Rivera, MD, MBA, MRO, FAPA

May 21st 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

6 Predictions for Digital Psychiatry in 2021

Related Content

No Screens Before Bed: Teen Smartphone Use at Bedtime Predicts Overnight Phone Activity

Artificial Intelligence in Psychopharmacology: Promise and Pitfalls, With Roy Perlis, MD

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

Harm Reduction for Behavioral Addiction in the Digital Age

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Seltorexant as Adjunctive Therapy for MDD With Insomnia

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD